BGM0504 Phase 2 Obesity Trial: Dual GLP-1/GIP Results

The BGM0504 phase 2 obesity trial reported mean weight loss of up to 18.33% after 24 weeks in Chinese adults with overweight or obesity who did not have diabetes. In this randomized, double-blind, placebo-controlled study, participants received once-weekly BGM0504 at 5 mg, 10 mg, or 15 mg, or placebo. Weight reductions increased with dose: 10.68%, 16.07%, and 18.33%, compared with a 0.13% increase in the placebo group.

These findings add peer-reviewed human evidence to research on medicines that act on more than one incretin pathway. They do not show that BGM0504 is better than <a href="https://glp1place.com/tools/compound/semaglutide/”>semaglutide or tirzepatide, and they do not establish long-term safety or regulatory approval. The study included 120 participants, lasted 24 weeks, and involved a specific population. Gastrointestinal adverse events were common.

The full publication appeared in Diabetes, Obesity and Metabolism on September 17, 2026. The PubMed record for the BGM0504 phase 2 obesity trial provides the primary study details, including reported endpoints, dosing groups, efficacy findings, pharmacokinetics, and adverse-event data.

What is BGM0504?

BGM0504 is an investigational dual incretin agonist designed to activate both the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. Its development approach resembles the broader dual-agonist strategy used by tirzepatide, but the molecules are not identical and cannot be assumed to have the same clinical profile.

GLP-1 receptor activation can reduce appetite, slow gastric emptying, improve glucose-dependent insulin secretion, and suppress inappropriate glucagon signaling. GIP biology is more context dependent. In combination with GLP-1 activity, GIP receptor activity may affect insulin secretion, adipose-tissue metabolism, energy balance, and tolerability. The central research question is whether activating both pathways together can produce greater or more sustainable metabolic effects than activating the GLP-1 receptor alone.

BGM0504 is not an approved weight-management product. It remains an investigational compound under evaluation in clinical trials. Phase 2 findings can support further testing, but they do not establish routine clinical use.

Earlier BGM0504 research included a phase 1 dose-escalation study in healthy volunteers and a separate phase 2 study in Chinese adults with type 2 diabetes. Those studies provided preliminary pharmacokinetic, glycemic, tolerability, and weight-related data. The September 2026 paper is a separate development milestone because it studied adults with overweight or obesity without diabetes and used body-weight change as its primary endpoint.

How the BGM0504 phase 2 obesity trial was designed

The study was a multicentre, randomized, double-blind, placebo-controlled phase 2 trial. A total of 120 participants were assigned equally across four groups:

The primary endpoint was the percentage change in body weight from baseline to week 24. Secondary measures included absolute weight change, waist circumference, the percentage of participants reaching prespecified weight-loss thresholds, pharmacokinetic exposure, and safety outcomes.

The trial was not a head-to-head comparison with semaglutide or tirzepatide. A placebo-controlled result can show whether a candidate had an effect beyond the study control, but it cannot establish superiority over an approved or competing investigational medicine. Differences in titration, treatment duration, baseline weight, diabetes status, geographic population, adherence, and statistical analysis can materially affect reported weight-loss percentages.

Weight-loss results were dose dependent

The main finding was a dose-response pattern. At week 24, mean body-weight change from baseline was:

• 5 mg BGM0504: minus 10.68%.
• 10 mg BGM0504: minus 16.07%.
• 15 mg BGM0504: minus 18.33%.
• Placebo: plus 0.13%.

All three BGM0504 doses were statistically superior to placebo, with reported p values below 0.0001. Waist-circumference findings moved in the same direction. Mean reductions were 8.88 cm with 5 mg, 12.71 cm with 10 mg, and 14.38 cm with 15 mg, compared with a 1.03 cm reduction in the placebo group.

The dose-response pattern supports the biological plausibility of the findings. When higher exposure is associated with progressively larger changes in a prespecified endpoint, researchers have more confidence that the effect is related to the investigational treatment rather than random variation alone. The study also reported an approximately linear dose-exposure relationship across the evaluated range, which may inform future research design.

Still, group-average percentages are not a forecast for every participant. The trial does not show whether weight reduction would continue beyond 24 weeks, plateau, reverse after treatment discontinuation, or be maintained over several years.

How BGM0504 compares with the incretin research landscape

BGM0504 enters a field that includes selective GLP-1 receptor agonists, dual GLP-1/GIP agonists, GLP-1/glucagon candidates, triple agonists, amylin combinations, and oral small-molecule programs. GLP1Place has separately reviewed first-human data for UBT251, phase 2 U.S. data for mazdutide, and phase 3 findings for survodutide. Those reports provide context, but the candidates use different receptor strategies and were tested in different populations.

The key limitation is the absence of a direct comparator in the BGM0504 obesity trial. It is not methodologically sound to place the 18.33% result beside figures from semaglutide, tirzepatide, or retatrutide trials and declare a winner. Useful comparative evidence requires similar study populations, baseline characteristics, treatment periods, titration rules, and analysis populations.

For example, a 24-week phase 2 study can produce a different percentage than a 68-week or 72-week phase 3 trial because weight change is time dependent. Early discontinuations, treatment exposure, lifestyle counseling, and the selected estimand can also affect the headline number.

The result is best interpreted as a substantial placebo-controlled signal, not a confirmed ranking against established therapies. Larger and more diverse studies would be needed to assess whether the findings can be reproduced across populations, including people with type 2 diabetes, cardiovascular disease, and participants outside China.

Safety and tolerability findings

Treatment-emergent adverse events occurred in 96.7% of participants in the 5 mg group, 93.5% in the 10 mg group, 100.0% in the 15 mg group, and 86.7% in the placebo group. Drug-related adverse events were reported in 53.3%, 80.6%, 93.1%, and 40.0%, respectively.

The most common selected adverse events were gastrointestinal, including nausea, diarrhea, and vomiting. The publication reported one serious adverse event in the 10 mg group. No treatment-emergent adverse event led to trial withdrawal.

These observations are limited by the study’s size and duration. A 120-person, 24-week trial cannot fully characterize uncommon events or long-term outcomes. Larger exposure and longer follow-up would be needed to evaluate durability, delayed adverse events, nutritional effects, gallbladder outcomes, pancreatitis-related questions, cardiovascular outcomes, and effects associated with substantial weight reduction.

The high frequency of adverse events in the placebo group also matters when interpreting tolerability. Clinically relevant questions include event severity, duration, relationship to dose escalation, effect on treatment continuation, and whether medical intervention was needed.

Development context

The BGM0504 findings reinforce continued scientific interest in dual incretin development. Programs can differ in molecular structure, exposure, receptor balance, administration frequency, and other pharmacological features even when they target the same receptors.

For obesity-drug research, placebo-controlled phase 2 results are an important early signal, but later development generally requires larger studies and more complete safety characterization. Head-to-head trials may be especially informative when developers seek to show meaningful differences from existing incretin medicines.

The study also illustrates the increasingly international nature of obesity research. Important phase 2 evidence is emerging from China and other regions, while U.S. and European programs continue to test related mechanisms. This broadens the evidence base but makes population differences relevant when interpreting generalizability.

BGM0504 could become relevant to a broader metabolic research strategy if later trials confirm effects on glycemia, waist circumference, blood pressure, lipids, liver fat, or other cardiometabolic measures. At present, these remain research questions rather than established clinical benefits.

Regulatory context

BGM0504 is investigational and is not approved by the U.S. Food and Drug Administration for weight loss, diabetes, or any other indication. A peer-reviewed trial publication is not authorization to market a compound and does not establish that products using the same name outside regulated clinical research are authentic, sterile, correctly dosed, or manufactured under appropriate controls.

Clinical-trial percentages can be repeated in marketing claims without the limitations of the underlying research. The published trial used a defined investigational product, controlled enrollment, protocol-based follow-up, and formal safety assessment. Those conditions cannot be assumed outside the trial.

The FDA has published concerns regarding unapproved GLP-1 drugs used for weight loss. BGM0504 should also be distinguished from approved dual-incretin treatment: it is not tirzepatide, and this publication does not establish equivalence, interchangeability, or superiority. Regulatory decisions depend on a complete development package that includes manufacturing controls, nonclinical evidence, clinical pharmacology, pivotal efficacy trials, and adequate safety exposure.

What future BGM0504 research would need to show

The near-term research question is confirmation in larger studies rather than immediate market entry. Important evidence gaps include longer treatment duration, more detailed adverse-event characterization, outcomes in people with type 2 diabetes, and evidence across more diverse populations.

Comparative evidence may ultimately be more informative than another small placebo-controlled trial. A randomized study against an established incretin medicine, with adequate duration and prespecified measures of weight maintenance, body composition, cardiometabolic health, and treatment persistence, could better clarify BGM0504’s clinical position.

Researcher takeaways

• The efficacy signal is substantial: Mean weight loss reached 18.33% with the reported 15 mg study group at week 24, with a clear dose-response relationship.
• The control group matters: Placebo participants had a 0.13% mean increase, creating a large treatment-control separation in this trial.
• The trial was small: Only 120 participants were randomized, limiting precision for uncommon adverse events.
• The population was specific: Participants were Chinese adults with overweight or obesity without diabetes, so generalization requires additional trials.
• The study was not head to head: No direct comparison with semaglutide or tirzepatide was performed.
• Gastrointestinal tolerability remains central: Nausea, diarrhea, and vomiting were prominent selected adverse events, particularly as dose increased.
• Long-term outcomes are unknown: The publication does not establish weight maintenance after discontinuation, cardiovascular benefit, or long-term safety.
• Pharmacokinetics support further study: The reported approximately linear dose-exposure relationship may assist later dose-ranging research, but does not establish an optimal clinical dose.

Researchers evaluating the incretin field should avoid treating receptor count as a guaranteed predictor of clinical superiority. More receptor activity can produce greater metabolic effects, but it can also increase gastrointestinal burden, complicate dose escalation, or create pharmacodynamic trade-offs. The overall benefit-risk profile, rather than mechanism alone, will determine whether BGM0504 becomes differentiated.

Consumer awareness notes

The September 2026 publication describes an investigational research program, not an approved treatment recommendation. A study reporting results under controlled conditions does not verify products using the same compound name outside regulated clinical research.

Claims that BGM0504 is interchangeable with an approved medicine or “stronger than” semaglutide or tirzepatide are not supported by this trial because no direct comparison was performed. The narrower, evidence-based conclusion is that BGM0504 produced substantial, dose-dependent weight loss versus placebo in a 24-week phase 2 trial of Chinese adults without diabetes.

What happens next for BGM0504?

The next stage of development would need to focus on confirmation and differentiation. Larger trials could clarify whether the magnitude of weight loss persists across broader populations and whether the safety profile remains manageable at scale. Investigators would also need to assess treatment duration, discontinuation, and weight regain.

Participant-level distributions will also matter. Reporting the proportions of participants reaching prespecified weight-loss thresholds can help show whether a group average reflects broad benefit or highly variable individual responses. Measures of waist circumference and body composition may further clarify the nature of observed weight change.

For regulators and clinicians, the central question is not only whether BGM0504 can reduce body weight. This study suggests an effect in the studied population. The more difficult question is whether later evidence demonstrates a favorable overall benefit-risk profile, reliable manufacturing, durable results, and meaningful clinical outcomes in a field that already includes effective incretin therapies.

For now, the BGM0504 phase 2 obesity trial is a meaningful pipeline update: a randomized study showing strong short-term, dose-dependent weight loss alongside frequent gastrointestinal adverse events. It advances the evidence base but does not resolve how BGM0504 compares with current medicines or whether the effect will translate into long-term clinical benefit.

Frequently Asked Questions

What did the BGM0504 phase 2 obesity trial find?

The trial found dose-dependent mean body-weight reductions of 10.68% with 5 mg, 16.07% with 10 mg, and 18.33% with 15 mg after 24 weeks. The placebo group had a mean 0.13% increase. All three BGM0504 groups were statistically superior to placebo.

What is BGM0504?

BGM0504 is an investigational once-weekly dual agonist designed to activate both the GLP-1 receptor and the GIP receptor. It is being studied for obesity and type 2 diabetes, but it is not an FDA-approved medicine.

Was BGM0504 compared directly with semaglutide or tirzepatide in this obesity trial?

No. The September 2026 obesity trial compared BGM0504 with placebo, not with semaglutide or tirzepatide. Direct comparisons require randomized head-to-head trials using similar populations, treatment durations, titration schedules, and endpoints.

What side effects were reported with BGM0504?

Gastrointestinal adverse events, including nausea, diarrhea, and vomiting, were the most common selected treatment-emergent adverse events. One serious adverse event occurred in the 10 mg group, and no treatment-emergent adverse events led to trial withdrawal.

Is BGM0504 approved for weight loss?

No. BGM0504 remains investigational. The phase 2 results support further clinical development but do not establish approval, routine clinical use, long-term safety, or superiority over currently approved medicines.

How large was the BGM0504 obesity study?

The trial randomized 120 Chinese adults with overweight or obesity who did not have diabetes. Participants were assigned to once-weekly BGM0504 at 5 mg, 10 mg, or 15 mg, or to placebo, for 24 weeks.